Back to News
Market Impact: 0.2

Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Source: globenewswire.com

Healthcare & BiotechCompany FundamentalsProduct Launches
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

ATTO-1310 showed preliminary clinical proof-of-concept in chronic pruritus and high-itch atopic dermatitis (AD), supporting the program’s early efficacy signal. The company expects complete Phase 1b data in Q4 2026, extending the timeline for catalysts and keeping near-term upside modest.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

mildly positive

Sentiment Score

0.25

More News

From AllMind Research

Browse all research